GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab) in patients with vasculitis
3 April 2013 | By GlaxoSmithKline
GSK announced the start of a Phase III study...
List view / Grid view
3 April 2013 | By GlaxoSmithKline
GSK announced the start of a Phase III study...
3 April 2013 | By GlaxoSmithKline
Marketing authorisation for quadrivalent (four-strain) influenza vaccine...
25 March 2013 | By GlaxoSmithKline
GSK received a Complete Response letter...
7 March 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the submission of a Marketing Authorisation Application for albiglutide...
19 February 2013 | By GlaxoSmithKline
The NDA for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI has been accepted...
15 February 2013 | By GlaxoSmithKline
The FDA has granted a priority review designation to dolutegravir...
7 February 2013 | By GlaxoSmithKline
GSK announced submission of a Marketing Authorisation Application...
5 February 2013 | By GlaxoSmithKline
“We are very pleased with the outcome of this transaction..."
1 February 2013 | By GlaxoSmithKline
GSK announced the start of COMBI-AD...
28 January 2013 | By GlaxoSmithKline
GSK and Biological E. announced an agreement to form a 50/50 joint venture...
24 January 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013...
22 January 2013 | By GlaxoSmithKline
As a global healthcare company, at GSK we believe we have a responsibility to help people make healthier choices...
14 January 2013 | By GlaxoSmithKline
Albiglutide is not yet approved as a treatment for type 2 diabetes...
9 January 2013 | By GlaxoSmithKline
GSK and Theravance announced the submission of a regulatory application...
19 December 2012 | By GlaxoSmithKline
Six-month primary treatment period results...